Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06760156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

StatusRecruiting
PhasePhase 2
Started2025-03-19
View on ClinicalTrials.gov ↗

Amendment history

2026-03-30
3 amendments v4-v6
3 re-verifications since 2025-08-28, no change to tracked fields
2025-05-05
Study Status v3
Start date2024-12-19→2025-03-19
2025-02-04
Study Status v2
Start dateestimated 2025-01→confirmed 2024-12-19
2025-01-06
Study Identification, Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 3 of 3 entries
Study title-17 characters
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
2024-12-30
Original filing
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Trial Details
NCT Number NCT06760156
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Incyte Corporation
Conditions Large B-cell Lymphoma
Enrollment 28 participants
Start Date 2025-03-19
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-03